|
| As
a
supporter
of
th
|
|
 |
|
 |
As a supporter of the PTO rules, this brief is very iesirntteng. On the one hand, it is not a particularly strong brief. On the other, it finally gets into the guts of the policy issues that the PTO all but ignored in the PI briefing. It also creates a strategic dilemma for GSK: do you address the amicus arguments and risk highlighting them, or do you ignore them and hope the court does as well?
|
 |
|
 |
|
|
|
|
|
|
(VISITOR) AUTHOR'S NAME
Nasrhul
MESSAGE TIMESTAMP
20 december 2014, 04:54:35
AUTHOR'S IP LOGGED
117.177.46.218
|
|
|
|
